Program
Anti-CD44v9 Antibody-drug Conjugate AMT-116
Also written as “AMT-116” and “AMT-116 CAR-T cells”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma, led by 2 companies.
Drug pageAnti-CD44v9 Antibody-drug Conjugate AMT-116: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Multitude Therapeutics | 44 open or running | phase 3since Jul 13, 2026 | Feb 2, 2023 | Dec 30, 2026phase 1 · NCT05725291 |
| Imunopharm Technologyits history only | 10 open or running | phase 2since Sep 6, 2021 | Sep 6, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Multitude Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 2, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05725291 · 80 planned · United States, American Samoa, Australia
- Dec 20, 2024Phase 2 study in Advanced Solid TumorsNCT06782334 · 144 planned · China
- May 10, 2026Phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)NCT07590531 · 118 planned · China
- Jul 13, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07718737 · 512 planned · United States, Australia
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Advanced Solid TumorNCT05725291
- May 30, 2027Primary completion: phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)NCT07590531
- Mar 30, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07718737
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) CD44 variant 9 (CD44v9), ”NCIt, by rule
Studies
All 4 Multitude Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07718737Carcinoma, Non-Small-Cell Lung · United States, Australia | 3 | Recruiting | Mar 30, 2028 | 512 |
| NCT07590531Advanced Non-small Cell Lung Cancer (NSCLC) · China | 2 | Recruiting | May 30, 2027 | 118 |
| NCT06782334Advanced Solid Tumors · China | 2 | Recruiting | Jun 30, 2026 | 144 |
| NCT05725291Advanced Solid Tumor · United States, American Samoa, Australia | 1 | Recruiting | Dec 30, 2026 | 80 |
How it is read
Names in the registry
- “AMT-116”, 4 entries
- “AMT-116 CAR-T cells”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.